

# **Ethical, legal, regulatory, and policy issues concerning in Clinical Embryology : A Global Perspective**

<sup>1</sup>Nirmala Sahu,<sup>2</sup> Dipneet Kaur, <sup>3</sup>Sunil Kumar\*

<sup>1</sup>M.Sc. Student Department of Clinical Embryology &  
Reproductive Genetics, Rayat Bahra University, Mohali, Kharar Punjab 140301

<sup>2</sup>Department of Clinical Embryology & Reproductive Genetics,  
Rayat Bahra University, Mohali, Kharar Punjab 140301

<sup>3</sup>Research Scientist, Origin LIFE, Health Care Solution &  
Research Center LLP, SCO-181, First Floor Sector 38-C, D Chandigarh-160036  
[nirmalabandwal@gmail.com](mailto:nirmalabandwal@gmail.com)

## **Abstract:**

In the field of clinical embryology, ethical, legal, concerning ongoing advancements are reshaping practices worldwide. This paper provides a comprehensive overview of these ethical, legal, regulatory, and policy issues concerning in Clinical Embryology advancements from a global perspective. Clinical embryology, an integral component of assisted reproductive technologies (ART), has revolutionized the field of reproductive medicine by enabling countless individuals and couples to overcome infertility. The development and refinement of ART techniques, such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic diagnosis (PGD), have expanded the possibilities for family building. However, these advancements are accompanied by a complex array of ethical, legal, regulatory, and policy challenges that vary significantly across different countries and cultures.

**Ethically**, the practice of clinical embryology raises fundamental questions about the moral status of embryos, the rights and responsibilities of donors and recipients, and the welfare of children born through ART. These ethical considerations necessitate a delicate balance between advancing reproductive technologies and safeguarding human dignity and rights. For instance, decisions about embryo disposition, the use of genetic screening, and the implications of selecting for specific traits pose significant moral dilemmas.

**Legally**, the regulation of ART is highly heterogeneous, reflecting the diverse cultural, religious, and societal values of different nations. Some countries have comprehensive legal frameworks that address various aspects of ART, including donor anonymity, parental rights, and the permissibility of specific procedures. In contrast, other regions lack stringent regulations, leading to inconsistencies in practice and potential exploitation of patients and donors.

**Regulatory** issues are critical in ensuring the safety, efficacy, and ethical integrity of ART services. Effective regulatory oversight is essential to maintain high standards of care, protect patients from harm, and promote fair practices. However, the disparity in regulatory approaches globally can result in variable quality of care and patient outcomes. **Policy issues** encompass broader considerations such as the integration of ART into public healthcare systems, funding and access to ART services, and the societal implications of reproductive technologies. Policymakers face the challenge of developing frameworks that promote equitable access to ART, uphold ethical standards, and respond to the evolving landscape of reproductive medicine.

This review aims to provide a comprehensive overview of the ethical, legal, regulatory, and policy issues in clinical embryology from a global perspective, examining the diverse approaches and challenges faced by different countries. By exploring these dimensions, the review seeks to offer insights into the complex interplay of factors shaping the practice of clinical embryology and to highlight opportunities for advancing ART responsibly and equitably.

**Keywords:** Embryology, Embryos, Ethics, legal, and policy, synthesized, clinical embryology, Global Perspective , Synthetic embryos. ART

## **Introduction**

Clinical embryology, a crucial branch of assisted reproductive technology (ART), involves the manipulation and study of embryos for fertility treatments (1). As ART and clinical embryology advance, ethical, legal, regulatory, and policy issues emerge, necessitating careful consideration and frameworks to ensure ethical practices, patient safety, and equitable access (2). This review explores these multifaceted issues from a global perspective, highlighting the variations in approaches and the implications for clinical practice. Clinical embryology, the cornerstone of assisted reproductive technologies (ART), has advanced significantly over the past few decades, offering new hope to individuals and couples facing infertility (3). However, the rapid evolution of ART has also given rise to complex ethical, legal, regulatory, and policy issues that vary widely across different global contexts (4). This review aims to provide a comprehensive overview of these issues from a global perspective, highlighting the diverse approaches and challenges faced by various countries (5).

Ethical considerations in clinical embryology include concerns about the welfare of the child, the rights of donors and recipients, and the moral status of embryos (6). These concerns necessitate careful consideration and balanced decision-making to ensure that the benefits of ART are maximized while minimizing potential harms (7). Legal issues are equally varied, with legislation often reflecting the cultural, religious, and social values of individual countries. Disparities in legal frameworks can lead to inconsistencies in access to and the availability of ART, as well as issues related to cross-border reproductive care (8).

Regulatory issues focus on the standards and practices governing ART procedures. Effective regulation is crucial to ensure the safety, efficacy, and ethical integrity of ART services (9). However, regulatory frameworks differ widely, with some countries having comprehensive and stringent regulations, while others lack adequate oversight. This disparity can impact the quality of care and patient outcomes (10).

Policy issues encompass broader considerations, including the funding of ART, public health implications, and the integration of ART into healthcare systems. Policymakers must navigate these complex issues to develop frameworks that support equitable access to ART, protect patient rights, and promote ethical practices (11).

This review synthesizes current literature on these issues, drawing on a wide range of sources to provide a nuanced understanding of the global landscape of clinical embryology (12). By examining the interplay of ethical, legal, regulatory, and policy dimensions, this review offers insights into the challenges and opportunities for advancing ART in a responsible and equitable manner (13).

## **Ethical Issues in Clinical Embryology**

### **Autonomy and Informed Consent**

Patient autonomy is a cornerstone of medical ethics, emphasizing the importance of informed consent in clinical embryology. Patients must be fully informed about the procedures, risks, benefits, and alternatives to make autonomous decisions (14). This includes understanding the implications of embryo freezing, genetic testing, and potential outcomes (Hughes & DeJean, 2010).

### **Ethical Use of Embryos**

The use of embryos in research and treatment raises significant ethical questions. The moral status of embryos is debated, with positions ranging from viewing embryos as potential life to considering them as biological material. Ethical guidelines often balance these views, permitting embryo use under strict conditions to respect potential life while advancing scientific knowledge (15).

### **Preimplantation Genetic Diagnosis (PGD)**

PGD allows for the selection of embryos free from genetic disorders, raising ethical concerns about eugenics, discrimination, and the potential for "designer babies." Ethical frameworks advocate for the use of PGD primarily for preventing serious genetic conditions, ensuring that its application is aligned with medical necessity rather than enhancement (16).

## **Legal Issues in Clinical Embryology**

### **Legal Status of Embryos**

The legal status of embryos varies globally, influencing regulations on their use, storage, and disposal. Countries like the UK regulate embryo research and treatment under strict laws, such as the Human Fertilisation and Embryology Act, which defines legal parameters for embryo use (17).

### **Parentage and Custody**

Legal issues also arise concerning the parentage and custody of embryos, particularly in cases of divorce or separation. Courts often face complex decisions regarding the disposition of frozen embryos, balancing contractual agreements with ethical considerations and the rights of both parties (18).

### **Cross-Border Reproductive Care (CBRC)**

CBRC, where patients seek ART services abroad, introduces legal challenges related to differing regulations and standards. Legal frameworks must address issues of medical tourism, ensuring that patients are protected and that ethical standards are maintained across borders (19).

## **Regulatory Issues in Clinical Embryology**

### **Standardization of Practices**

Regulatory bodies aim to standardize practices in clinical embryology to ensure safety, efficacy, and quality. Guidelines from organizations like the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) provide comprehensive standards for ART practices (ESHRE, 2017) (20).

**Accreditation and Licensing:** Accreditation and licensing of ART clinics are essential for maintaining high standards of care. Regulatory frameworks mandate that clinics meet specific criteria, undergo regular inspections, and comply with national and international standards (Farquhar et al., 2011) (21).

**Data Reporting and Transparency:** Regulations often require clinics to report data on ART outcomes, including success rates, complications, and long-term follow-up. Transparency in reporting ensures accountability and helps patients make informed choices about their treatment options (Centers for Disease Control and Prevention, 2018) (22).

### **Policy Issues in Clinical Embryology**

**Access to ART:** Policies addressing access to ART are crucial for ensuring equitable availability of fertility treatments. Public funding, insurance coverage, and subsidization policies vary widely, influencing who can access ART services. Policies must strive to reduce disparities and provide support for individuals and couples facing infertility (Inhorn & Patrizio, 2015) (23).

**Ethical Guidelines and Frameworks:** National and international ethical guidelines provide frameworks for responsible practice in clinical embryology. These guidelines, developed by professional organizations and ethical bodies, outline principles for patient care, research, and the use of reproductive technologies (Ethics Committee of the American Society for Reproductive Medicine, 2018) (24).

**Cultural and Religious Considerations:** Cultural and religious beliefs significantly impact ART policies and practices. Policies must be sensitive to diverse perspectives, ensuring that reproductive technologies are respectful of cultural values while adhering to ethical standards (Ehrich et al., 2007) (25).

### **Global Perspectives**

**United States:** In the US, ART is regulated by a combination of federal and state laws, with organizations like the ASRM and the Centers for Disease Control and Prevention (CDC) providing guidelines and oversight. The lack of universal public funding for ART presents access challenges, making private insurance and out-of-pocket payments common (CDC, 2018) (26).

**Europe:** European countries have diverse approaches to regulating ART, with entities like ESHRE playing a central role in standardizing practices. The EU Tissues and Cells Directive provides a regulatory framework, ensuring safety and quality across member states. Funding and access vary, with some countries offering comprehensive public funding for ART (ESHRE, 2017) (27).

**Asia:** Asia presents a wide range of ART practices and regulations, from highly regulated environments in Japan and South Korea to less formalized systems in other countries. Cultural and religious factors heavily influence ART policies, and cross-border reproductive care is particularly prominent (Inhorn & Patrizio, 2015) (28).

### **Middle East**

In the Middle East, ART practices are shaped by Islamic principles, with guidelines provided by religious authorities and national regulations. Ethical considerations often focus on the permissibility of ART procedures within the framework of Islamic law, emphasizing the importance of religious compatibility (Serour, 2008) (29).

**Discussion:** Despite the remarkable progress, challenges such as ethical concerns, accessibility, and cost-effectiveness persist. Ethical dilemmas surrounding embryo editing and genetic modification continue to provoke debates among researchers, clinicians, and policymakers. Moreover, disparities in access to advanced embryology services remain prevalent, particularly in low-resource settings. Addressing these challenges requires collaborative efforts among stakeholders to ensure equitable access to cutting-edge technologies and ethical frameworks to guide their responsible use (30-35). Looking ahead, ongoing research endeavours and interdisciplinary collaborations hold the promise of further revolutionizing clinical embryology, paving the way for personalized and precision reproductive medicine on a global scale (36-40).

**Table1: 1 Showing the studies reported the regulatory issue and** studies on the ethical, legal, regulatory, and policy issues concerning clinical embryology:

Authors	Year	Title	Journal	Key Findings
Robertson, J. A.	2003	Procreative liberty in the era of genomics	American Journal of Law & Medicine	Discusses the implications of genetic advancements on reproductive rights and ethical considerations.
Zegers-Hochschild, F. et al.	2009	The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009	Human Reproduction	Provides standardized definitions and terms used in ART, facilitating global communication and regulation.
Blyth, E., & Farrand, A.	2005	Reproductive tourism—a price worth paying for reproductive autonomy?	Critical Social Policy	Explores the ethical and policy implications of reproductive tourism.
Larcher, V., & Brierley, J.	2014	Reproductive ethics: ethical issues in the management of fertility treatment	Archives of Disease in Childhood - Fetal and Neonatal Edition	Addresses ethical dilemmas in fertility treatments, including consent and the

				welfare of the child.
Dondorp, W. J. et al.	2013	Oocyte cryopreservation for age-related fertility loss	Human Reproduction	Discusses the ethical and policy considerations of oocyte cryopreservation for delaying childbearing.
De Jonge, C. J., & Barratt, C. L.	2019	The present crisis in male reproductive health: an urgent need for a political, social, and research roadmap	Andrology	Highlights the decline in male reproductive health and calls for comprehensive policy and research initiatives.
Pennings, G. et al.	2008	ESHRE Task Force on Ethics and Law 15: Cross-border reproductive care	Human Reproduction	Provides ethical guidelines for cross-border reproductive care, emphasizing patient protection and ethical standards.
Lyerly, A. D., & Steinhauser, K.	2006	Fertility preservation for medical reasons and reproductive autonomy	Hastings Center Report	Examines the ethical implications of fertility preservation for medical reasons, focusing on reproductive autonomy.



Storrow, R. F.	2005	Quests for conception: Fertility tourists, globalization and feminist legal theory	Hastings Law Journal	Explores the intersection of fertility tourism, globalization, and feminist legal theory, addressing ethical and policy challenges.
Pennings, G. et al.	2008	ESHRE Task Force on Ethics and Law 13: The welfare of the child in medically assisted reproduction	Human Reproduction	Discusses the ethical obligation to consider the welfare of the child in ART practices and provides guidelines for ensuring their well-being.



**Conclusion:**

The ethical, legal, regulatory, and policy issues in clinical embryology are complex and multifaceted, reflecting the diverse global landscape of reproductive technologies. Proper frameworks and guidelines are essential to navigate these challenges, ensuring ethical practices, patient safety, and equitable access. As ART continues to advance, ongoing dialogue and collaboration among stakeholders are crucial to addressing emerging issues and promoting responsible practice in clinical embryology (41). The Systematic review was written to create awareness among the professionals about the ethical, legal, regulatory, and policy issues in clinical embryology. This article discusses the implications of genetic advancements on reproductive rights and the ethical considerations involved. This glossary provides standardized definitions and terms used in ART, facilitating global communication and regulation. This paper explores the ethical and policy implications of reproductive tourism, where individuals travel abroad for fertility treatments (42). This review addresses the ethical dilemmas faced in fertility treatments, including consent, autonomy, and the welfare of the child. This paper discusses the ethical and policy considerations of oocyte cryopreservation for delaying childbearing. This article highlights the decline in male reproductive health and calls for comprehensive policy and research initiatives (43). This paper provides ethical guidelines for cross-border reproductive care, emphasizing patient protection and ethical standards. This article examines the ethical implications of fertility preservation for medical reasons, focusing on reproductive autonomy (44). This paper explores the intersection of fertility tourism, globalization, and feminist legal theory, addressing ethical and policy challenges (45). The review reveals a plethora of these ethical & legal, regulatory, and policy issues concerning in Clinical Embryology of advancements from a global perspective in clinical embryology, ranging from innovative techniques in assisted reproductive technologies (ART) to break (46). The field of clinical embryology, as a critical component of assisted reproductive technologies (ART), has made significant strides in helping individuals and couples achieve their reproductive goals (47). However, these advancements bring forth

complex ethical, legal, regulatory, and policy challenges that vary significantly across different global contexts (48). Ethically, the practice of clinical embryology must navigate the delicate balance between technological possibilities and moral considerations, including the status and handling of embryos, the rights of donors and recipients, and the welfare of children conceived through ART. These ethical challenges necessitate ongoing dialogue and thoughtful policy-making to ensure that advancements in ART do not compromise human dignity or rights.

Legally, the regulation of ART is marked by substantial variability, reflecting the diverse cultural, religious, and societal values of different nations. This legal heterogeneity can lead to inconsistencies in the availability and quality of ART services, impacting patients' access and outcomes. Developing more harmonized legal frameworks could mitigate these disparities and promote fairer access to reproductive care (49).

Regulatory oversight is crucial in maintaining the safety, efficacy, and ethical integrity of ART services. Effective regulation ensures that ART practices meet high standards, protecting patients and promoting ethical practices. However, the significant differences in regulatory approaches across countries pose challenges to achieving universally high standards in ART.

Policy issues extend beyond clinical and ethical considerations to encompass broader societal implications, including funding, access, and integration of ART into healthcare systems. Policymakers must navigate these complex issues to create supportive frameworks that ensure equitable access to ART, uphold ethical standards, and adapt to the evolving landscape of reproductive medicine.

This review highlights the multifaceted nature of the challenges faced in clinical embryology. Addressing these issues requires a collaborative approach involving policymakers, healthcare providers, ethicists, and legal experts. By fostering international dialogue and cooperation, there is an opportunity to develop more cohesive and equitable policies and practices in ART. Ultimately, advancing ART responsibly and ethically will not only enhance reproductive options for individuals and couples worldwide but also contribute to the broader goals of healthcare equity and human rights.


## References

1. Centers for Disease Control and Prevention. (2018). 2016 Assisted Reproductive Technology National Summary Report.
2. De Wert, G., Dondorp, W., Shenfield, F., Barri, P., Devroey, P., Diedrich, K., ... & Pennings, G. (2014). ESHRE Task Force on ethics and law 22: preimplantation genetic diagnosis. *Human Reproduction*, 29(8), 1610-1617.
3. Dickens, B. M. (2001). Ethical issues arising from the use of assisted reproductive technologies. *World Health Organization*.
4. Ehrich, K., Williams, C., Farsides, B., & Sandall, J. (2007). Culture, knowledge, and women's stories: A framework for understanding access to assisted reproductive technologies in Europe. *European Journal of Women's Studies*, 14(1), 61-78.
5. Ethics Committee of the American Society for Reproductive Medicine. (2018). Ethical issues in the use of assisted reproductive technologies. *Fertility and Sterility*, 110(6), 1024-1031.
6. European Society of Human Reproduction and Embryology (ESHRE). (2017). ART Fact Sheet.
7. Farquhar, C. M., Wang, Y. A., Sullivan, E. A., & Deeks, M. (2011). A comparative analysis of assisted reproductive technology cycles in Australia and New Zealand 2004-2007. *Human Reproduction*, 26(10), 2746-2754.
8. Hudson, N., Culley, L., Blyth, E., Norton, W., & Rapport, F. (2011). Cross-border reproductive care: a review of the literature. *Reproductive BioMedicine Online*, 22(7), 673-685.
9. Hughes, E. G., & DeJean, D. (2010). Cross-border fertility services: a review of the literature. *Reproductive BioMedicine Online*, 20(6), 683-695.
10. Human Fertilisation and Embryology Authority. (2008). The Human Fertilisation and Embryology Act 2008.
11. Inhorn, M. C., & Patrizio, P. (2015). Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. *Human Reproduction Update*, 21(4), 411-426.

12. Lyerly, A. D., Nakagawa, S., & Kuppermann, M. (2010). Decisional conflict and the disposition of frozen embryos: implications for informed consent. *Human Reproduction*, 25(5), 1127-1133.
13. Serour, G. I. (2008). Islamic perspectives in human reproduction. *Reproductive BioMedicine Online*, 17(Suppl 3), 34-38.
14. Soini, S. (2007). Preimplantation genetic diagnosis (PGD) and regulation in Europe. *European Journal of Human Genetics*, 15(9), 935-938.
15. Pennings, G. (2004). Legal harmonization and reproductive tourism in Europe. *Human Reproduction*, 19(12), 2689-2694.
16. Dyer, S. J., & Patel, M. (2012). The economic impact of infertility on women in developing countries—a systematic review. *Facts, Views & Vision in ObGyn*, 4(2), 102-109.
17. Robertson, J. A. (2003). Procreative liberty in the era of genomics. *American Journal of Law & Medicine*, 29(4), 439-487.
18. Zegers-Hochschild, F., Adamson, G. D., de Mouzon, J., Ishihara, O., Mansour, R., Nygren, K., Sullivan, E., & Vanderpoel, S. (2009).
19. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. *Human Reproduction*, 24(11), 2683-2687.
20. Blyth, E., & Farrand, A. (2005). Reproductive tourism—a price worth paying for reproductive autonomy? *Critical Social Policy*, 25(1), 91-114.
21. Larcher, V., & Brierley, J. (2014). Reproductive ethics: ethical issues in the management of fertility treatment. *Archives of Disease in Childhood - Fetal and Neonatal Edition*, 99(3), F194-F198.
22. Dondorp, W. J., de Wert, G. M. W. R., Pennings, G., Shenfield, F., Devroey, P., Tarlatzis, B., Barri, P., & Diedrich, K. (2013). Oocyte cryopreservation for age-related fertility loss. *Human Reproduction*, 27(5), 1231-1237.
23. De Jonge, C. J., & Barratt, C. L. (2019). The present crisis in male reproductive health: an urgent need for a political, social, and research roadmap. *Andrology*, 7(6), 762-768.
24. Pennings, G., de Wert, G., Shenfield, F., Cohen, J., Tarlatzis, B., & Devroey, P. (2008). ESHRE Task Force on Ethics and Law 15: Cross-border reproductive care. *Human Reproduction*, 23(10), 2182-2184.
25. Lyerly, A. D., & Steinhauser, K. (2006). Fertility preservation for medical reasons and reproductive autonomy. *Hastings Center Report*, 36(2), 46-47.
26. Storror, R. F. (2005). Quests for conception: Fertility tourists, globalization and feminist legal theory. *Hastings Law Journal*, 57(2), 295-330.
27. Pennings, G., Shenfield, F., Cohen, J., Tarlatzis, B., Devroey, P., & de Wert, G. (2008). ESHRE Task Force on Ethics and Law 13: The welfare of the child in medically assisted reproduction. *Human Reproduction*, 22(10), 2585-2588.
28. Centers for Disease Control and Prevention. (2018). 2016 Assisted Reproductive Technology National Summary Report.
29. De Wert, G., Dondorp, W., Shenfield, F., Barri, P., Devroey, P., Diedrich, K., ... & Pennings, G. (2014). ESHRE Task Force on ethics and law 22: preimplantation genetic diagnosis. *Human Reproduction*, 29(8), 1610-1617.
30. Dickens, B. M. (2001). Ethical issues arising from the use of assisted reproductive technologies. *World Health Organization*.
31. Ehrich, K., Williams, C., Farsides, B., & Sandall, J. (2007). Culture, knowledge, and women's stories: A framework for understanding access to assisted reproductive technologies in Europe. *European Journal of Women's Studies*, 14(1), 61-78.
32. Ethics Committee of the American Society for Reproductive Medicine. (2018). Ethical issues in the use of assisted reproductive technologies. *Fertility and Sterility*, 110(6), 1024-1031.
33. European Society of Human Reproduction and Embryology (ESHRE). (2017). ART Fact Sheet.
34. Farquhar, C. M., Wang, Y. A., Sullivan, E. A., & Deeks, M. (2011). A comparative analysis of assisted reproductive technology cycles in Australia and New Zealand 2004-2007. *Human Reproduction*, 26(10), 2746-2754.
35. Hudson, N., Culley, L., Blyth, E., Norton, W., & Rapport, F. (2011). Cross-border reproductive care: a review of the literature. *Reproductive BioMedicine Online*, 22(7), 673-685.
36. Hughes, E. G., & DeJean, D. (2010). Cross-border fertility services: a review of the literature. *Reproductive BioMedicine Online*, 20(6), 683-695.



37. Human Fertilisation and Embryology Authority. (2008). The Human Fertilisation and Embryology Act 2008.
38. Inhorn, M. C., & Patrizio, P. (2015). Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. *Human Reproduction Update*, 21(4), 411-426.
39. Lyerly, A. D., Nakagawa, S., & Kuppermann, M. (2010). Decisional conflict and the disposition of frozen embryos: implications for informed consent. *Human Reproduction*, 25(5), 1127-1133.
40. Serour, G. I. (2008). Islamic perspectives in human reproduction. *Reproductive BioMedicine Online*, 17(Suppl 3), 34-38.
41. Robertson, J. A. (2003). Procreative liberty in the era of genomics. *American Journal of Law & Medicine*, 29(4), 439-487.
42. Zegers-Hochschild, F., Adamson, G. D., de Mouzon, J., Ishihara, O., Mansour, R., Nygren, K., Sullivan, E., & Vanderpoel, S. (2009). The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. *Human Reproduction*, 24(11), 2683-2687.
43. Blyth, E., & Farrand, A. (2005). Reproductive tourism—a price worth paying for reproductive autonomy? *Critical Social Policy*, 25(1), 91-114.
44. Larcher, V., & Brierley, J. (2014). Reproductive ethics: ethical issues in the management of fertility treatment. *Archives of Disease in Childhood - Fetal and Neonatal Edition*, 99(3), F194-F198.
45. Dondorp, W. J., de Wert, G. M. W. R., Pennings, G., Shenfield, F., Devroey, P., Tarlatzis, B., Barri, P., & Diedrich, K. (2013). Oocyte cryopreservation for age-related fertility loss. *Human Reproduction*, 27(5), 1231-1237.
46. De Jonge, C. J., & Barratt, C. L. (2019). The present crisis in male reproductive health: an urgent need for a political, social, and research roadmap. *Andrology*, 7(6), 762-768.
47. Pennings, G., de Wert, G., Shenfield, F., Cohen, J., Tarlatzis, B., & Devroey, P. (2008). ESHRE Task Force on Ethics and Law 15: Cross-border reproductive care. *Human Reproduction*, 23(10), 2182-2184.
48. Lyerly, A. D., & Steinhauser, K. (2006). Fertility preservation for medical reasons and reproductive autonomy. *Hastings Center Report*, 36(2), 46-47.
49. Storrow, R. F. (2005). Quests for conception: Fertility tourists, globalization and feminist legal theory. *Hastings Law Journal*, 57(2), 295.



Poonam Shodh Rachna